Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for investors to stir. Pharmaxis’ latest clinical trial (MF-101) focuses on bone marrow cancer myelofibrosis and potential treatment with their hero drug, PXS-5505. Having already proven the drug’s tolerability and efficacy in terms of absorption, distribution,
Read More
With more pressure than ever on the healthcare system, scalability is everything. How can we expand the system to meet increased demands by users? Pacific Knowledge Systems (ASX: PKS) is addressing this complex issue through their technology stack by providing software applications to better capture, apply and manage human expertise to enhance business performance and
Read More
There’s been a small bump in the road in Cyclopharm’s (ASX: CYC) plans to secure regulatory approval for Technegas™, their proprietary technology for lung imaging. Technegas™ comprises ultra-fine radioactive labelled carbon that is exposed to high heat to create a gas that can be inhaled by the patient. The gas allows for comprehensive imaging to
Read More
Since the beginning of the pandemic, where trust in the public transport network sent Aussies towards new and used cars in droves, Autosports Group (ASX: ASG) is continuously brought upon by their excellent sales, adding dealership John Newell Mazda to their network via acquisition. The deal will secure 80% of the Mazda dealership for $12
Read More
Given Woolworths Group (WOW) is a well owned stock, many clients may be asking what to do with the Endeavour Group (EDV) shares. We provide some initial thoughts below. Thoughts upfront – we would suggest investors hold their EDV shares as we conduct further due diligence on EDV. We suspect any re-rating in EDV shares will come more from margin expansion
Read More
Sadly, 1 in 7 women will be diagnosed with breast cancer at some stage in their life. That’s 1 in 7 mothers, daughters, aunties, girlfriends, wives, friends and nieces. In the last 10 years, breast cancer diagnosis has increased by 36% and remains the second most common cause of death from cancer among females. Health
Read More
